Mankind Pharma and Innovent Biologics Partner to Commercialize Innovative Immunotherapy in India – Healthcare News

Mankind Pharma Limited on Thursday announced that it has partnered with Innovent Biologics to exclusively license and commercialize sintilimab, an advanced PD-1 immunotherapy, in the Indian market.

This strategic collaboration aims to address critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region, the company said in a statement.

The cancer has become major health concern in Indiawith its burden projected to reach 29.8 million DALYs by 2025, according to the National Cancer Registry Program1. In response to this pressing challenge, the partnership between Mankind Pharma and Innovent Biologics provides a critical solution that aims to address the rising incidence of cancer and improve patient outcomes across the country.

Toripalimab will strengthen the oncology portfolio of Dr. Reddy in India

Where Universal Health Coverage in India?

First indigenous gene therapy in humans for hemophilia A shows significant positive results

Metropolis Healthcare acquires Core Diagnostics to enhance advanced cancer testing capabilities

“Sintilimab, marketed as TYVYT (sintilimab injection) in China, is a high-quality PD-1 immunoglobulin G4 monoclonal antibody jointly developed by Innovent and Eli Lilly. Its mechanism of blocking the PD-1/PD-L1 pathway reactivates T cells, enhancing the body’s natural ability to target and eliminate cancer cells (i). The drug has demonstrated remarkable efficacy and favorable safety in several major cancers, with eight indications approved in China, including non-small cell lung cancer, liver cancer, gastric cancer, esophageal cancer, endometrial cancer and Hodgkin lymphoma. TYVYT® (sintilimab injection), is one of the leading immunotherapy options, has already benefited millions of cancer patients since its launch in 2018. This versatile immunotherapy has the potential to make a significant impact for oncology patients in India,” the company said. said in a statement.

According to the agreement, Mankind Pharma will have exclusive rights to register, import, marketsells and distributes sintilimab in India. Innovent will oversee the production and supply of the product, ensuring consistent availability and adherence to high quality standards.

“Mankind Pharma is delighted to partner exclusively with Innovent Biologics to launch sintilimab in India. This revolutionary immunotherapy represents a significant advance in cancer treatment, offering new hope to patients battling a range of cancers. By bringing this innovative therapy to the Indian market, we are committed to improving patient outcomes and strengthening our leadership position in oncology. Mankind Pharma brings its extensive pharmaceutical experience and extensive distribution network to this partnership with a strong field force of over 16,000 employees and over 13,000 distributors across India. This ecosystem will be crucial in ensuring widespread access to sintilimab in urban and rural markets. The partnership is more than a commercial agreement – ​​it is a commitment to transform cancer care in India by making innovative treatments available to a wider patient population,” said Mr. Atish Majumdar – Senior President – ​​Sales and MarketingMankind Pharma Limited.

Innovent will be eligible to receive upfront, regulatory and commercial payments, it added.

“Innovent is delighted to partner with Mankind Pharma to introduce our innovative PD-1 inhibitor sintilimab in India, offering new hope to patients battling various forms of cancer. By leveraging Mankind Pharma’s extensive network and deep expertise, we are confident that sintilimab will be quickly accessible to patients across the country. Together, we are committed to advancing patient care in India by making cutting-edge treatments more affordable and accessible,” said Dr. Samuel Zhang, Business Director of Innovent Biologics.